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Abstract: Saliva may provide interesting advantages as matrix for compliance measurements, pharmacokinetic studies 
and therapeutic drug monitoring in resource limited countries. We investigated the feasibility of using saliva for 
compliance monitoring of zidovudine (ZDV), lamivudine (3TC) and nevirapine (NVP) in 29 HIV-1 infected patients from 
Rwanda. ZDV, 3TC and NVP drug levels were quantified by an LC/MS-MS method in plasma and stimulated saliva 
samples and compared using Bland-Altman analysis. Seven patients demonstrated undetectable saliva ZDV levels while 
five out of these seven also showed no 3TC salivary concentrations. For the other samples, we observed a good agreement 
between salivary and plasma concentrations of each antiretroviral drug. A significant relation between the difference in 
saliva and plasma ZDV concentrations and the average ZDV concentration in the two matrices was deduced as follows: y 
= -380.15 + 1.79 x. The log saliva and plasma concentration difference of both 3TC and NVP was consistent across the 
range of average log concentration. Overall, we showed large agreement limits suggesting a wide inter patient variability 
that may result in non-reliable plasma level predictions from saliva drug measurements. Therefore, our results indicate 
that saliva may serve as a valuable tool only for NVP compliance testing because of its high salivary concentration. 
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INTRODUCTION 
 Oral fluids have been introduced since the early eighties 
as a matrix for detection and quantification of drugs and 
drugs of abuse. Compared to blood sampling, whole saliva 
has several important advantages: fluid collection is non-
invasive, skin irritation or bruising in patients with poor 
venous access can be avoided and sample collection is safe. 
Further, saliva is a cost-effective tool for screening a large 
population and allows multiple sample collections at any 
time of the day [1]. However, saliva cannot be used as a 
simple substitute for blood testing since pharmacokinetic 
characteristics of many drugs are more complex in saliva 
than in blood [2]. 
 Few studies investigated the use of saliva for therapeutic 
drug monitoring (TDM) and/or compliance control studies in 
HIV infected patients undergoing antiretroviral therapy 
(HAART) [3-6]. Rolinski and collaborators have shown a 
good correlation between plasma and salivary concentrations 
of zidovudine (ZDV) in ten HIV-infected patients suggesting 
that stimulated saliva might be an appropriate specimen for 
ZDV-TDM [3]. Plasma nevirapine (NVP) concentrations 
were strongly correlated with stimulated saliva levels from 
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NVP-treated adults [4]. Although indinavir concentrations in 
saliva were shown to be related to plasma concentrations, the 
authors of the study did not recommend saliva for TDM 
because of significant intra and inter individual variations 
[5]. However, a correlation between two matrix values does 
not automatically imply a good agreement between two 
methods of measurement. The Bland and Altman method [7] 
is the method of choice to assess graphically agreement 
between two body fluids. Using this method, agreement 
between plasma and non stimulated NVP saliva levels in 
children on multi-HAART regimen was reported [6]. 
 The majority of HIV-infected individuals are living in 
Sub-Saharan Africa. More than 75 000 individuals received 
HAART in Rwanda in 2009. Although virological and 
immunological outcomes to HAART in Rwanda were 
comparable to western countries [8-10], routine supervision 
and adherence data are limited [10]. The aim of our study 
was to investigate the agreement between salivary and 
plasma concentrations of ZDV, lamivudine (3TC) and NVP 
for adherence and pharmacokinetic studies in resource 
limited settings. 
MATERIAL AND METHODS 
Study Group 
 The study was a cross-sectional design in a prospective 
cohort initiated by the ESTHER (“Ensemble de Solidarité 
Thérapeutique Hospitalière en Réseau”) project at the HIV 
clinic of the Treatment Research AIDS Center (TRAC) in 
Kigali. All participants signed a written consent form before 
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being enrolled into the survey. HAART treatment consisted 
of ZDV/3TC (Combivir
®
, GlaxoSmithKline, London) and 
NVP (Viramune
®
, Boehringer Ingelheim, Ingelheim) taken 
twice daily. The total daily dose was 600 mg ZDV, 300 mg 
3TC and 400 mg NVP. Adherence to the antiretroviral 
(ARV) treatment was controlled by frequent questionnaires 
and pill counts. Patient characteristics are summarized in 
Table 1. 
Table 1. Characteristics of the 29 HIV-1 Infected Patients 
 
Patient Characteristics Value 









27 – 60  













3 – 588  









aCD4 cell counts were measured using a FACScalibur™ Flow Cytometer (Becton 
Dickinson, Franklin Lakes, USA); n, number of patients; SD, standard deviation; 
WHO, World Health Organization. 
 
Sample Collection and Preparation 
 Blood and saliva samples were collected during a routine 
consultation, 3 to 5 hours (mean 225 min) after the last drug 
intake. Saliva was collected using a Salivette
®
 (Sarstedt AG 
& Co., Nümbrecht, Germany) containing a roll-shaped saliva 
collector impregnated with citric acid to stimulate salivation. 
The swab was chewed for one to two minutes and placed 
back in the insert. Plasma and salivettes were shipped on dry 
ice to Luxembourg and stored at -20°C before analysis. Then 
the salivettes were centrifuged for 5 minutes at 3 500 g to 
collect the saliva while the swabs were washed with an ethyl 
acetate/methanol mixture (1/1, v/v). Extracts were 
evaporated and the residual saliva added to the previously 
collected saliva. One milliliter of saliva or plasma was then 
mixed to 1 ml ammonium buffer at pH 9.5 and Mebeverine 
which served as internal standard. Unbound ARVs were 
extracted with solid phase extraction cartridges as described 
earlier [11, 12]. After evaporating the extracts to dryness 
under nitrogen at 40°C, the residues were reconstituted in 
100 l ammonium formate buffer (pH 3.8) for quantitative 
analysis. 
Antiretroviral Drug Concentration Measurements 
 Detection and quantification of ARV drugs was carried 
out on a high performance liquid chromatography system 
coupled to a LCQ
™
 Duo Ion Trap Detector (Thermo 
Electron, Zellik, Belgium) equipped with an electrospray 
ionization interface and operated in both positive and 
negative ion mode. The separation of sample components 
was achieved on an XTerra
®
 MS C18 column (5 μm particle 
size, 3.9 x 150 mm, Waters, Overijse, Belgium), equipped 
with a similar pre-column (10 mm). The mobile phase 
consisted of a mixture of 5 mM ammonium formate buffer at 
pH 3.8 and acetonitrile. Validation parameters for the 
quantification method included determination of extraction 
yield, establish interday and intraday accuracy and 
repeatability as well as verification of absence of ion 
suppression in the calibration range. Six point calibration 
curves covering the therapeutic ranges of the ARV drugs 
were established and all r
2
 were  0.98. 
Statistics 
 ARV concentrations were analyzed using R v.2.10.1. 
Applying the Bland-Altman method [13], log differences 
between saliva and plasma measurements were plotted 
against their average log concentration to determine the bias 
and the 95% limits of agreement (bias ± 1.96 standard 
deviation, SD). The Shapiro-Wilk test was used to assess 
normality of log differences, one condition of the Bland-
Altman method. A linear regression analysis was used to 
confirm the lack of relationship between the two 
measurements and the average concentration (both expressed 
in log). If saliva minus plasma levels were still related to the 
average concentration after log transformation, a regression 
approach for non-uniform differences was applied [14] and 
regression based limits of agreement for the difference in 
drug concentrations were calculated. According to the Bland 
and Altman's recommendation, 95% limits of agreement for 
a saliva/plasma (S/P) ratio with back-transformed log values 
was then calculated. 
RESULTS 
 Mean and median concentrations of unbound ZDV, 3TC 
and NVP in saliva and plasma of the 29 HIV-1 infected 
Rwandan patients are given in Table 2. Seven patients 
demonstrated saliva ZDV concentrations below the detection 
limit with two also showing undetectable plasma ZDV. 
Among these seven patients, five had indiscernible 3TC 
salivary levels. One patient was considered as an outlier for 
saliva ZDV concentrations because the range observed was 
10 fold higher than the physiological concentrations. These 
saliva and plasma concentrations have not been included in 
the statistical analysis. NVP was detected in all plasma and 
saliva samples (concentrations ranging from 207 to 9 730 
ng/ml in saliva and from 417 to 8 917 ng/ml in plasma). 
 Average unbound ZDV was higher in the saliva 
compartment than in the plasma with a mean S/P ratio of 4.0 
± 9.8 (mean ± SD) whereas unbound 3TC plasma 
concentrations were higher than salivary concentrations in all 
patients (mean S/P ratio = 0.3 ± 0.2, Table 2). Mean 
concentrations of unbound NVP were similar in plasma and 
in saliva with a mean S/P ratio of 1.5 ± 2.1. For NVP, 15/29 
patients had a S/P ratio < 1 indicating a high heterogeneity of 
the blood-saliva diffusion between individuals. Interestingly, 
most patients (10/15) with a ratio < 1 for NVP had also a 
ratio < 1 for ZDV. 
 A relationship between the differences of plasma and 
saliva drug concentrations and the average concentrations in 
the two measurements was established for each drug 
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(p<0.05; Table 3). Therefore, each sample was finally 
defined by the log saliva (S) – log plasma (P) difference and 
the average log concentrations [7, 13, 14]. The log-
transformed measurement differences followed the normal 
distribution for each drug. The ZDV plot revealed a linear 
relationship between the log difference and average log 
concentration whereas the log difference of 3TC and NVP 
were consistent across the range of average log 
concentrations (Fig. 1). The log-based linear regression 
model confirmed the independence of the log(S)-log(P) 
differences and log average for both 3TC and NVP (Table 
3). The plots revealed a good agreement between salivary 
and plasma concentrations with only one sample outside the 
limits of agreement for NVP (Fig. 1). However, the 
estimated limits of agreement between the two matrices were 
relatively high for both 3TC and NVP (within 0.03 and 1.13 
for the 3TC S/P ratio and 0.06 and 9.09 for the NVP S/P 
ratio). Using linear regression analyses, we could confirm a 
significant relationship between the log(S) – log(P) 
differences and the average ZDV log concentration (p< 0.05, 
Table 3). Therefore, regression based limits of agreement for 
non-uniform differences in ZDV concentrations were 
calculated as previously described [14]. As shown in Fig. 
(2), the differences in ZDV saliva and plasma concentrations 
increased with increasing drug concentrations. The statistical 
relation between the ZDV difference saliva – plasma (y) and 
the mean concentrations (x) was expressed as follows: y = -
380.15 + 1.79 x. A good agreement between the two values 
was observed; only one ZDV sample was outside the limits 
of agreement but large 95% limits of agreement were 
obtained (-1 104.84 + 1.79 x, 344.54 + 1.79 x). 
DISCUSSION 
 A number of clinical trials have demonstrated that 
plasma concentrations of antiretroviral drugs are an 
important factor for treatment response [15]. Concentration 
based antiretroviral drug dose reduction might increase 
access to safer therapy while preserving viral load 
suppression [16, 17]. In contrast, inadequate drug 
concentrations, often due to drug adherence failure, may lead 
to appearance of toxicity or drug resistance mutations. Lack 
of compliance of HAART-treated patients is estimated to 
occur between 40% and 60% of patients [18]. Combined 
with resistance tests, assessment of adherence may prove to 
be useful in developing countries [19] to preserve limited  
 
second line treatment. Genotypic resistance testing has been 
initiated in Rwanda [8, 9, 20] and close monitoring of 
patients at risk has been proposed as a relevant strategy [21]. 
To our knowledge, our study is the first study evaluating the 
utility of saliva in a Sub-Saharan population for which 
specific genetic background, medications and diet might 
influence differently antiretroviral pharmacokinetics both in 
plasma and saliva. 
 Although we showed a good agreement between saliva 
and plasma levels of ZDV, 3TC and NVP, the high inter 
individual variability represented by large 95% limits of 
agreement does not allow an accurate quantitative deduction 
of plasma ARV levels based on saliva ARV concentrations. 
In plasma, the inter patient variability of antiretroviral drugs 
has been reported by us [11, 12] and by others [22, 23] and 
has been attributed to genetic influences, diet and/or 
presence of other drugs and diseases [24-26]. In saliva, the 
parameters responsible for drug concentration variations may 
be salivary flow rate, salivary pH, and drug 
pharmacokinetics. The salivary flow rate varies as a function 
of nutritional and emotional state, age, presence of diseases 
and/or presence of other drugs [27]. High inter individual but 
low intra individual variation of saliva pH has been 
described [28]. Variations in S/P ratios between individuals 
may also be linked to differences in bound and unbound drug 
concentrations in plasma. This variation was reported to be 
high for NVP [29], relatively low for ZDV [30] and to vary 
as a function of age for 3TC [31]. 
 Predicting plasma ARV concentrations from saliva is 
based on the assumption that saliva drug concentrations are 
related to unbound blood levels of the drug. The blood – 
saliva transfer of drugs appears to be a passive diffusion 
process. The S/P ratio has been described as a function of 
drug pKa, of differences in drug protein binding in blood and 
saliva and the pH in the saliva and plasma [32]. In normal 
physiological conditions (blood pH of 7.4 and a saliva pH 
range from 5.5 – 7.9), considering a pKa of 9.7 and an 
unbound drug fraction of 0.81 for ZDV, 4.3 and 0.64 for 
3TC and 2.8 and 32 for NVP respectively, the S/P ratios for 
the three drugs were estimated to vary from 0.3 to 64 for 
ZDV, 0.1 to 2.0 for 3TC and 0.1 to 1.0 for NVP depending 
on the saliva pH. In our study, the average S/P values of 
unbound ZDV, 3TC and NVP were 4.0, 0.3 and 1.5 
respectively. With its pKa of 9.7, ZDV is present in plasma 
in a non-ionized form and has fewer difficulties to diffuse  
 
Table 2. Mean and Median of Antiretroviral Drug Concentrations in Plasma and Saliva 
 





n = 26 
205 (179) 
148 (107 - 286) 
n = 29 
1 349 (759) 
1 213 (837 - 1 965) 
n = 29 
3 045 (2 302) 






n = 21 
498 (789) 
238 (84 - 612) 
n = 24 
372 (438) 
197 (161 - 350) 
n = 29 
2 769 (2 513) 
1 558 (462 - 4 547) 
Saliva/Plasma ratio 
Mean (SD) 
n = 21 
4.0 (9.8) 
n = 24 
0.3 (0.2) 
n = 29 
1.5 (2.1) 
aUnbound plasma concentrations in ng/ml; bUnbound saliva concentrations in ng/ml; IQR, interquartile range; n, number of patients; SD, standard deviation. 








































Fig. (1). Zidovudine (ZDV), lamivudine (3TC) and nevirapine 
(NVP) Bland-Altman plots representing the differences between log 
saliva and log plasma as a function of the average log 
concentrations. The ZDV plot showed a relationship between the 
log differences and the mean log concentrations. A good agreement 













Fig. (2). Linear regression plot between the saliva minus plasma 
concentration differences and the average concentrations in the two 
matrices following the equation y = -380.15 + 1.79 x. One sample 
was outside the limits of agreement. 
Table 3. Statistical p-Values of the Linear Regression Analysis for 
Zidovudine, Lamivudine and Nevirapine Bland-Altman 
Plots 
 
 Zidovudine Lamivudine Nevirapine 
p-value
a
 8.62 E-10 0.02 0.04 
p-value
b
 0.00224 0.055 0.171 
aRelation between saliva minus plasma difference and average concentrations; 
bRelation between difference of log saliva and log plasma and average log 
concentrations. 
 
through the cell membranes than the ionized 3TC (pKa of 
4.3). Thus, unbound 3TC concentrations were found to be 
higher in plasma than in saliva. Independent of the presence 
of ionized NVP molecules at pH 7.4, the mean unbound 
salivary concentration of NVP was as high as the plasma 
levels that might be a consequence of its greater lipophilicity 
as compared to ZDV and 3TC. 
 Based on correlation coefficients, ZDV and NVP 
concentrations were previously significantly related in the 
two matrices [3, 4, 6]. We also observed a significant 
correlation by the non parametric Spearman correlation rank 
test for each ARV (data not shown). However, the use of 
correlation coefficients to compare two different biological 
compartments is misleading [7, 13, 14] as the physiological 
parameters modulating the drug concentrations in the two 
body fluids are diverse. Using the Bland-Altman analysis, 
the 3TC and NVP plots indicated a non equal distribution in 
the two matrices among the patients, while the ZDV plot 
revealed a linear relationship between the log difference in 
saliva and plasma concentrations and the mean log 
concentrations. Although an accurate prediction of ZDV 
plasma concentrations can be deduced from a linear 
equation, the large 95% limits of agreement as well as the 7 
samples without detectable saliva concentrations have to be 
taken into account and may hint towards other influent 
parameters in these patients. 
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 TDM is recommended to decipher drug interactions or to 
explain poor response to treatment and side-effects related to 
high dose of antiretroviral drugs in HIV-infected patients. 
Considering that we did not address the question of TDM in 
our study that only included a limited number of patients, the 
usability of saliva seems ambiguous. In conclusion, our data 
suggest that saliva may only be used for NVP as a valuable 
tool for compliance testing in resource limited countries. 
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